Literature DB >> 2901485

Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein.

N Seki1, T Nagao, K Komori, H Suzuki.   

Abstract

We observed the effects of carvedilol, a novel beta adrenoceptor blocker, on electrical responses of smooth muscle cells produced by endogenous and exogenous norepinephrine (NE) in isolated canine mesenteric artery and vein. Carvedilol inhibited the NE-induced depolarization in the artery but not in vein, with potencies equivalent to prazosin, i.e., carvedilol blocked alpha 1 adrenoceptors in arterial smooth muscles. Stimulation of perivascular nerves evoked an excitatory junction potential (e.j.p.) and a slow depolarization in these vascular smooth muscles. Carvedilol inhibited the slow depolarization evoked in the artery but not in the vein, with no marked inhibition of the e.j.p.s. High concentrations (10(-5) M) of carvedilol inhibited the e.j.p., slow depolarization, and also the compound action potentials of sympathetic nerve bundles running along the mesenteric vessels, suggesting that these inhibitions were due to local anesthetic actions. The e.j.p. amplitude was increased by isoprenaline and was decreased by NE. The NE and isoprenaline actions were antagonized by yohimbine and propranolol, respectively. Carvedilol inhibited the isoprenaline-actions but not the NE actions on the e.j.p., suggesting that this drug blocked prejunctional beta adrenoceptors but not the alpha 2 adrenoceptors. These results indicate that carvedilol blocks alpha 1 and beta adrenoceptors but not alpha 2 adrenoceptors in vascular tissues.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901485

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Altered responses to vasopressors of a patient medicated with carvedilol, pilsicainide and enalapril.

Authors:  Kumi Nakamura; Norihiko Fukami
Journal:  J Anesth       Date:  2013-12-24       Impact factor: 2.078

2.  Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.

Authors:  H Hashimoto; M Tanaka; A Kanda; A Akashi
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Comparison of the prejunctional beta-adrenoceptor stimulating actions of adrenaline and isoprenaline in the dog mesenteric vein.

Authors:  N Seki; H Suzuki
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

Review 4.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

5.  Opposite modulation of cotransmitter release in guinea-pig vas deferens: increase of noradrenaline and decrease of ATP release by activation of prejunctional beta-adrenoceptors.

Authors:  J Gonçalves; R Bültmann; B Driessen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

Review 6.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.

Authors:  T Wendt
Journal:  Clin Investig       Date:  1992

Review 8.  Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol--rationale for clinical use.

Authors:  G Sponer; W Bartsch; K Strein
Journal:  Clin Investig       Date:  1992

Review 9.  The pharmacology of carvedilol.

Authors:  R R Ruffolo; M Gellai; J P Hieble; R N Willette; A J Nichols
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Effects of carvedilol on serum lipids in hypertensive and normotensive subjects.

Authors:  H Seguchi; H Nakamura; N Aosaki; Y Homma; Y Mikami; S Takahashi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.